Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer

Jing Li; Jingjing Shao; Xunlei Zhang; Xin Chen; Wenjing Zhao; Hongyan Qian; Xiaopeng Cui; Xiaohui Jiang

doi:10.1155/2020/8781674

Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer

Gastroenterol Res Pract. 2020 Nov 20:2020:8781674. doi: 10.1155/2020/8781674. eCollection 2020.

Authors

Jing Li¹, Jingjing Shao¹, Xunlei Zhang^{1

2}, Xin Chen^{1

3}, Wenjing Zhao¹, Hongyan Qian¹, Xiaopeng Cui⁴, Xiaohui Jiang^{1

3}

Affiliations

¹ Cancer Research Center Nantong, Nantong Tumor Hospital & Affiliated Tumor Hospital of Nantong University, Nantong, China.
² Department of Oncology, Nantong Tumor Hospital & Affiliated Tumor Hospital of Nantong University, Nantong, China.
³ Department of General Surgery, Nantong Tumor Hospital & Affiliated Tumor Hospital of Nantong University, China.
⁴ Department of Gastrointestinal Surgery, Nantong University Affiliated Hospital, Nantong, Jiangsu, China.

Abstract

Background: Multiple studies have reported the significance of the systemic immune-inflammation index (SII) in the prognosis of colorectal cancer (CRC), but no consensus has yet been reached. The purpose of this study was to systematically assess the prognostic value of SII in patients with CRC.

Materials and methods: We performed a systematic literature search in PubMed, Embase, and the Cochrane Library for eligible studies. The correlation between pretreatment SII and overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC patients was evaluated by combining the hazard ratio (HR) and 95% confidence interval (CI).

Results: Twelve studies involving 3919 patients were included. Comprehensive analysis results showed that high SII indicated poor OS in CRC patients (HR = 1.777, 95% CI: 1.328-2.376). Compared with patients with low SII values, patients with high SII had lower PFS (HR = 1.658, 95% CI: 1.189-2.311). Subgroup analysis further verified the above results.

Conclusions: SII may be a noninvasive and powerful tool for predicting survival outcomes in CRC patients. However, more well-designed studies are needed to validate our findings.